16, 2025 — Two new studies have identified a possible way to block the progression of several forms of blood cancer using a drug already in clinical trials ... Jan. 3, 2025 — Tumor cells ...

Malignant cells with high delta-like ligand 4 (DLL4) expression interact with cancer-associated fibroblasts and endothelial cells via the DLL4-NOTCH signalling pathway to metastasise from primary CRC ...

Feb. 4, 2025 — Research has shown that a potential new targeted therapy for childhood brain cancer is effective in infiltrating and killing tumor cells in preclinical models tested in mice.

Dr. Weickert will present Pacylex at the OBIO® Investment Summit and Early Technology Showcase February 5-7, 2025, at the Arcadian Court & Loft, Toronto Mr. Kamdar will present Pacylex at the PWMC ...

The interactions between Notch, tumor cells, the tumor environment, and the immune system may influence the progression and the outcome of neoplastic processes and likely represent new targets of ...

Mechanical factors influence the initial fate of cancer cells after they have left a primary tumour. Blood-flow patterns from the primary tumour determine which organ the cells travel to first.

Part of that spike is due to rising rates of cancers that affect primarily women, including breast cancer and endometrial ...

Tumors contain a fraction of cancer stem cells that maintain the propagation ... We focused on the Notch pathway since Jagged-2, a Notch ligand was found to be overexpressed in the LSC samples.

It is part of the Notch signaling pathway ... to a poorer prognosis because it drives tumor growth and helps cancer cells survive longer. To keep Notch1 activity in check, it must be ...

Good news for the sector came January 23 when global pharmaceutical giant AstraZeneca plc announced an eye-popping $820 ...

Today, cancer has become one of the leading global tragedies. It occurs when a small number of cells in the body mutate, causing some of them to evade the body’s immune system and proliferate ...